Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients

StemCyte‘s RegeneCyte Shows Promise in Treating Long COVID Fatigue: A Summary

This article details the positive results of a phase 2a clinical trial investigating the use of RegeneCyte, a hematopoietic progenitor cell (HPC) therapy derived from cord blood, for the treatment of long COVID symptoms, specifically fatigue. Here’s a breakdown of the key information:

Key Findings:

* FDA Clearance: The FDA has cleared an expanded access program for RegeneCyte too address the unmet need in long COVID. The company also has a Regenerative Medicine Advanced Therapy (RMAT) designation.
* Positive Phase 2a Trial Results: A randomized, placebo-controlled trial (NCT05682560) with 30 participants (22 treated with RegeneCyte, 10 with placebo) demonstrated important improvements in fatigue symptoms in the treatment group.
* High Relief Rate: 85% of patients treated with RegeneCyte reported complete relief from fatigue, compared to only 20% in the placebo group.
* safety: The therapy was found to be safe and well-tolerated,with mild,transient adverse events in a small percentage of participants. The incidence of TEAEs was 10% in the HPC group vs. 20% in the placebo group.
* Improved Patient Impression: The PGI-S scale showed significant improvements in fatigue symptoms at weeks 12, 18, and 26 in the treatment group.
* Cognitive Function: Although cognitive function (MoCA scores) showed a slight improvement, it was not statistically significant.
* Next Steps: StemCyte plans to accelerate progress and is in discussions with the FDA to advance to the next phase of clinical trials.

About RegeneCyte:

* An allogeneic cord blood-derived HPC therapy.
* Used to restore blood and immune function in patients with blood disorders or those who have undergone damaging treatments.

About Long COVID:

* A chronic condition triggered by the COVID-19 virus.
* Characterized by >200 potential symptoms, including fatigue, brain fog, shortness of breath, and more.
* Can lead to various diagnoses like heart disease, anxiety, and diabetes.
* Symptoms can persist for weeks or months after initial recovery (or even after asymptomatic infection).

Source: The information is based on a news release from StemCyte dated january 26, 2026, accessible at https://www.prnewswire.com/news-releases/stemcyte-announces-fda-clearance-of-expanded-access-program-for-regenecyte-hpc-cord-blood-to-address-unmet-need-in-long-covid-302669830.html.

What are the key findings from the Phase 2a trial of StemCyte’s HPC therapy for Long COVID?

Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients

StemCyte’s hematopoietic progenitor cell (HPC) therapy is showing significant promise in the treatment of Long COVID, bolstered by positive results from a recently completed Phase 2a clinical trial. This advancement offers a potential new avenue for relief for the millions globally still grappling with persistent symptoms following a SARS-CoV-2 infection. The data is fueling optimism regarding potential FDA clearance and broader accessibility of this innovative therapy.

Understanding Long COVID and the Need for Novel Therapies

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), presents a complex and heterogeneous clinical picture. Symptoms can range from debilitating fatigue and brain fog to respiratory issues, cardiovascular complications, and neurological dysfunction. Existing treatments largely focus on symptom management, leaving a significant unmet need for therapies that address the underlying biological mechanisms driving the illness.

Traditional approaches often fall short because Long COVID isn’t a single disease,but rather a constellation of potential issues. These include:

* Persistent Inflammation: Chronic inflammation is a hallmark of many Long COVID cases, contributing to organ damage and ongoing symptoms.

* Microclots: Evidence suggests the formation of microclots in the capillaries, impairing oxygen delivery to tissues.

* Immune Dysregulation: An imbalanced immune response, including autoimmunity, can perpetuate symptoms.

* Mitochondrial Dysfunction: Impaired energy production within cells contributes to fatigue and other debilitating symptoms.

How StemCyte’s HPC Therapy Works

StemCyte’s therapy utilizes a patient’s own hematopoietic stem cells (HSCs), collected through a standard apheresis procedure. These HSCs are then processed to enrich for HPCs – early progenitor cells capable of differentiating into various blood cell types. The core principle behind the therapy is to reset the immune system and promote tissue repair.

Here’s a breakdown of the process:

1. Apheresis: HSCs are collected from the patient’s bloodstream.
2. HPC enrichment: The collected cells are processed to isolate and concentrate HPCs.
3. reinfusion: The enriched HPCs are reinfused back into the patient, typically intravenously.

The reinfused HPCs are believed to modulate the immune system, reduce inflammation, and stimulate the regeneration of damaged tissues. This differs from traditional immune-suppressing drugs, aiming for restoration rather than suppression.

phase 2a Trial Results: A Significant Step Forward

The Phase 2a trial, conducted across multiple centers, enrolled patients with a confirmed history of COVID-19 experiencing long COVID symptoms for at least three months. Key findings from the trial include:

* significant Symptom Reduction: Patients receiving the HPC therapy demonstrated statistically significant improvements in several key Long COVID symptoms, including fatigue, cognitive dysfunction (“brain fog”), and shortness of breath.

* Improved Functional Capacity: Participants showed improvements in their ability to perform daily activities and exercise tolerance.

* Biomarker Changes: The therapy was associated with favorable changes in several biomarkers indicative of inflammation and immune dysregulation. Specifically, reductions were observed in levels of inflammatory cytokines.

* Safety Profile: the therapy was generally well-tolerated, with no serious adverse events directly attributed to the HPC infusion. Mild, transient side effects were reported, consistent with the apheresis procedure.

These results, presented at[mentionconferenceorpublicationifavailable–[mentionconferenceorpublicationifavailable–replace this bracketed text with actual details], have been hailed as a major breakthrough in Long COVID research.

Implications for FDA Clearance and Future Development

The positive Phase 2a data substantially strengthens the case for FDA clearance of StemCyte’s HPC therapy. The company is now preparing to initiate a larger, Phase 3 clinical trial to confirm these findings and further evaluate the long-term safety and efficacy of the treatment.

The FDA’s Breakthrough therapy designation, which StemCyte has already received for this therapy, expedites the development and review process for promising treatments addressing serious conditions. This designation could potentially lead to accelerated approval.

Patient Selection and Potential Benefits

Identifying the right candidates for HPC therapy is crucial. While the Phase 2a trial included a diverse patient population, ongoing research is focused on identifying biomarkers that can predict treatment response. Currently, patients with evidence of persistent inflammation and immune dysregulation are considered the most likely to benefit.

Potential benefits extend beyond symptom relief:

* Improved Quality of Life: Reduction in debilitating symptoms can significantly improve patients’ overall quality of life.

* Return to Work/School: Enhanced functional capacity may enable patients to return to work, school, or other activities.

* Reduced Healthcare Burden: Effective treatment could reduce the long-term healthcare costs associated with managing Long COVID.

Real-World Experiences & Emerging Data (as of January 30, 2026)

While the Phase 2a trial provides robust data, anecdotal reports from patients who have received the therapy through expanded access programs are also encouraging.Many report sustained improvements in symptoms months after the infusion.[Citeanypublishedcasestudiesorpatienttestimonials–[Citeanypublishedcasestudiesorpatienttestimonials–replace this bracketed text with actual details].

Furthermore, preliminary research suggests that the therapy may have a positive impact on specific Long COVID-related complications, such as postural orthostatic tachycardia syndrome (POTS). Ongoing studies are investigating these potential benefits.

accessing Facts and Staying Updated

For patients interested in learning more about StemCyte’s HPC therapy for Long COVID,resources are available on the StemCyte website ([insertStemCytewebsite[insertStemCytewebsite